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Abstract
Non-functioning pituitary adenomas (NFA) are benign pituitary neoplasms not associated with clinical evidence of hormonal 
hypersecretion. A substantial number of patients with NFA have morbidities related to the tumor and possible recurrence(s), 
as well as to the treatments offered. Studies assessing the long-term mortality of patients with NFA are limited. Based on the 
published literature of the last two decades, overall, the standardized mortality ratios in this group suggest mortality higher 
than that of the general population with deaths attributed mainly to circulatory, respiratory and infectious causes. Women 
seem to have higher mortality ratios, and assessment of time trends suggests improvement over the years. There is no con-
sensus on predictive factors of mortality but those most consistently identified are older age at diagnosis and high doses of 
glucocorticoid substitution therapy. Well designed and of adequate power studies are needed to establish the significance of 
factors compromising the survival of patients with NFA and to facilitate improvements in long-term prognosis.
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Introduction
Non-functioning pituitary adenomas (NFA) or, as recently 
proposed, non-functioning pituitary neuroendocrine tumors 
[1] are benign pituitary neoplasms that arise from the adeno-
hypophyseal cells and are not associated with clinical evi-
dence of hormonal hypersecretion. They constitute 15–37% 
of all pituitary adenomas [2–4] and have a prevalence of 
70–220 per million inhabitants [2–5]. The absence of clini-
cal manifestations of hormonal hypersecretion relates with 
diagnostic delay and, with the exception of incidentally 
found ones, they are usually detected when they are large 
enough to cause pressure effects to surrounding structures. 
When treatment is indicated, surgery is the first option, com-
bined or not with adjuvant radiotherapy [6].
A substantial number of patients with NFA have mor-
bidities related to the tumor and possible recurrence(s), as 
well as to the treatments offered; visual deterioration and 
hypopituitarism are the most frequent [6–10]. As a result 
of these, the long-term survival of these patients may be 
compromised.
In this review, we have evaluated and summarised the 
literature published in the last two decades on the mortality 
of patients with NFA and potential factors affecting it. Series 
also involving subjects with other (para)sellar tumors and 
not analysing the outcomes of those with NFA separately 
were not included.
Mortality in patients with non‑functioning pituitary 
adenomas
Studies assessing the long-term mortality of patients with 
NFA are limited and, overall, they suggest mortality higher 
than that of the general population. A summary of the litera-
ture reporting standardized mortality ratios (SMR) that are 
included in this review is shown in Table 1.
Metaxia Tampourlou and Athanasios Fountas have contributed 
equally to this work.
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Nielsen et al. [11], in a series of 192 patients from three 
Danish centers treated surgically between 1985 and 1996 
(in 83% by transsphenoidal approach − 22% had received 
adjuvant radiotherapy), found SMR of 1.21 (95% CI, 
0.93–1.59); the median follow-up for the surviving subjects 
was 13.1 years and for those who died 4.6 years. SMR was 
significantly increased in women (2.11; 95% CI, 1.35–3.31) 
but not in men and the causes of death were not cardiovas-
cular (further details are not provided). Mortality was also 
reported similar in patients who had been offered radiother-
apy and in those having only surgery. The relatively small 
number of patients remains a limitation of this report. In 
a further study from the same centers covering the same 
period and including 160 patients [12], SMRs of patients 
with normal pituitary function, partial hypopituitarism or 
panhypopituitarism were not different from the general pop-
ulation; it should be noted, however, that the management 
of pituitary hormone deficits is not clarified in this paper.
Chang et al. [13], in a series of 663 patients with NFA 
managed between 1975 and 1995 (transsphenoidal approach 
in most of the cases − 51% had received adjuvant radiother-
apy) in US centers and followed up for a median time of 14 
years, reported that the study population had a significantly 
higher mortality rate than the general population; however, 
no SMRs or causes of death were provided.
Tomlinson et al. [14], in a series of 573 patients with 
NFA included in the West Midlands Hypopituitary database 
(42% of them also had radiotherapy), found SMR of 1.70 
(99% CI, 1.34–2.15) with the excess mortality explained 
by an increase in respiratory and cardio/cerebrovascular 
deaths. Mortality was increased in women comparatively 
with men (SMR 2.23; 99% CI, 1.60–3.11 vs. SMR 1.37; 
99% CI, 0.98–1.91, p = 0.006). It should be pointed out 
that this study may have been affected by selection bias, 
as it includes only subjects with NFA and hypopituitarism. 
Furthermore, almost one-third of the patients with gonado-
trophin deficiency did not receive replacement therapy and 
adrenocorticotropic hormone (ACTH) deficiency was treated 
with higher doses than currently used (15–30 mg hydrocor-
tisone per day). Finally, around 10% of the patients had no 
surgery and, therefore, no histological confirmation of the 
adenoma diagnosis.
Olsson et al. [15], in a series of 2795 patients identified in 
the Swedish National Patient Registry and followed up for 
a mean period of 7 years, reported a SMR of 1.10 (95% CI, 
1.00–1.20). Increased mortality was described in patients 
diagnosed before the age of 40 years (SMR 2.68; 95% CI, 
1.23–5.09), in women (SMR 1.29; 95% CI, 1.11–1.48) 
and in those treated with radiotherapy (SMR 2.67; 95% 
CI, 1.79–3.84). In contrast to males, females with hypopi-
tuitarism or diabetes insipidus had increased SMR (1.38; 
95% CI, 1.12–1.66 and 2.43; 95% CI, 1.26–4.25, respec-
tively). Deaths were attributed to infectious and circulatory 
diseases. A significant advantage of this study is its large 
sample size but a drawback is the validity of the diagnosis 
in the reviewed cases (when the identification criteria were 
checked in a group of 467 subjects, the presence of NFA 
was confirmed in 90.8% of them; 1172 patients diagnosed 
between 1997 and 2011 had no surgery or radiotherapy, 
thereby lacking histological confirmation and information on 
possible surgical treatments and radiotherapy were not avail-
able for those diagnosed before 1997). Furthermore, hypo-
pituitarism was defined by an entry of this term in the Reg-
istry and details on number of patients checked, diagnostic 
Table 1  Studies reporting standardized mortality ratios in patients with non-functioning pituitary adenoma (those reviewing a subgroup of a pre-
viously studied population are not included)
Study Country 
period 
covered
Number of patients Surgery/radiotherapy Follow-up (years) (range) Standardized mor-
tality ratio (95% CI)
Ntali et al. [8] UK
1963–2011
546 100%/29% Median
8.0 (1 month–48.5)
3.6 (2.9–4.5)
Nielsen et al. [11] Denmark
1985–1996
192 100%/22% Median
13.1 (8.0–20.0)
(surviving subjects)
4.6 (0–18.6)
(deceased subjects)
1.21 (0.93–1.59)
Tomlinson et al. [14] UK
1992–2000
573 (all had hypopituitarism) 90%/42% Not reported for patients with 
NFA
1.70 (1.34–2.15)
Olsson et al. [15] Sweden
1987–2011
2795 Patients diagnosed 
before 1997 (12%)
Treatment not avail-
able
Patients diagnosed 
after 1997 (88%)
52%/4%
Mean
7 (0–25)
1.10 (1.00-1.20)
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criteria, degree and management of hypopituitarism were 
not available. Assessment of time trends in mortality in a 
subgroup of patients from the same Registry revealed that 
in females, this was increased for those diagnosed between 
1997 and 2006 but not between 2007 and 2011 [16]. The 
authors reported that during the study period, the prevalence 
of diabetes insipidus and the use of surgery and radiotherapy 
had remained stable but the frequency of hypopituitarism 
had declined. Nonetheless, as in their previous study [15], 
details on the diagnosis and management of the pituitary 
hormone deficits were not available affecting the interpreta-
tion of the results.
Ntali et al. [8], in a series of 546 patients operated on for 
a macroNFA between 1963 and 2011 and followed up for a 
median period of 8 years in a UK center, reported SMR of 
3.6 (95% CI, 2.9–4.5). Transsphenoidal surgery had been 
offered to 97% of the patients and 29% of them had received 
adjuvant radiotherapy. SMR was 4.7 (95% CI, 2.7–7.6) for 
those operated before 1990 and 3.5 (95% CI, 2.8–4.4) for 
those operated after 1990. Main causes of death were due to 
cardio/cerebrovascular diseases (34%), infections (30%) and 
malignancies (29%). In a subset of patients with adequate 
clinical follow-up data (n = 436), the SMR was 3.8 (95% 
CI, 2.0–4.7); in this group, 97% of the patients had trans-
sphenoidal surgery, 25.3% had regrowth of the NFA and 
43.1% had received radiotherapy (adjuvant post-operative 
or for relapse).
Based on these data which mostly rely on European popu-
lations, overall, the SMR of patients with NFA are increased 
with deaths attributed mainly to circulatory, respiratory and 
infectious causes. Women seem to have higher mortality 
ratios and assessment of time trends suggests improvement 
over the years.
Predictive factors of mortality
Cox regression analyses have been performed in a number 
of studies aiming to identify predictive factors of mortality. 
A summary of the published data is discussed below. The 
confounding factors used in Cox model were often different 
between the studies and this may partially explain the vari-
ability of the results.
Age at diagnosis
Ntali et al. [8], have shown that age at diagnosis was an 
independent predictor of mortality [after adjustment for 
factors proven to be significant in univariate analysis in 
this series: radiotherapy, regrowth of tumor and untreated 
growth hormone (GH) deficiency] with shorter survival for 
older patients [Hazard ratio (HR) 1.10; 95% CI, 1.07–1.13, 
p < 0.001]. In this study, a significant difference in the rate of 
survival between subjects diagnosed before and after the age 
of 50 years was also noted (survival at 10 years 98.5% vs. 
80.9% respectively, p < 0.01). Similar results were described 
by Chang et al. [13] with HR 1.09 (95% CI, 1.08–1.84, 
p < 0.0001). On the other hand, Olsson et al. [15] reported 
that young age at diagnosis was a strong predictor of mortal-
ity with HR for those diagnosed at the age of 40 or earlier of 
3.47 (95% CI, 1.28–9.42, p = 0.015) for males and 4.20 (95% 
CI, 1.32–13.32, p = 0.015) for females. The explanation for 
this observation remains unclear.
Sex
Despite the increased SMRs reported in women, sex has not 
been confirmed as an independent predictor of mortality [8, 
13, 17]. The adjustment for possible confounding factors is 
a potential explanation for this discrepancy.
Radiotherapy
In most recent series of patients with NFA, radiotherapy has 
not shown to be an independent predictor of mortality [8, 13, 
18]. On the other hand, Olsson et al. [15] reported that radio-
therapy was a predictive factor of excess mortality (males 
HR 1.99; 95% CI, 1.15–3.42, p = 0.014; females HR 2.81; 
95% CI, 1.63–4.83, p < 0.0001). It should be mentioned, 
however, that only 4% of their patients had received irradia-
tion. Notably, in a subsequent study including a subgroup of 
patients diagnosed with NFA between 1997 and 2011 and 
with the end of the study extended for three further years, 
Olsson et al. [19] found that radiotherapy did not have an 
effect on the Cox model for mortality. Van Varsseveld et al. 
[20], in a series of 806 patients with NFA and severe GH 
deficiency identified from the Dutch National Registry of 
Growth Hormone Treatment in Adults (96% of them were 
treated with GH and 57% had received radiotherapy) and 
followed up for a median period of 10 years, found that after 
adjustment for relevant confounders (age, gender, treated 
ACTH insufficiency and GH replacement), mortality was not 
different between irradiated and non-irradiated patients. The 
impact of other pituitary hormone deficits and their manage-
ment was not taken into account in this study.
Pituitary hormone deficiencies
The clarification of the impact of hypopituitarism on the 
mortality of patients with NFA based on the published 
literature is confounded by a number of factors including 
the variable criteria applied for the diagnosis of pituitary 
hormone deficits (especially for studies covering long peri-
ods), the differences in the hormone substitution protocols 
between centers and between studies and the developments/
206 Pituitary (2018) 21:203–207
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improvements in the management of hypopituitarism over 
the years [21].
• GH deficiency: Ntali et al. [8] found that untreated GH 
deficiency was not an independent predictor of mortal-
ity. In this series, selection bias may have affected the 
reliability of the results, as in the UK, GH replacement 
is offered after prescreening of patients according to the 
National Institute of Clinical Excellence (NICE) guide-
lines and those with an optimal score in the Quality of 
Life assessment standardized questionnaire (Assessment 
of Growth Hormone Deficiency in Adults—AGHDA) are 
not candidates for treatment. O’Reilly et al. [18] reported 
that GH deficient patients were not at increased risk of 
death compared to those with intact GH secretion after 
adjusting for surgery, age at diagnosis, attained age, sex 
and radiotherapy. However, when considered separately, 
patients with untreated GH deficiency had higher mortal-
ity risk compared to those with treated GH deficiency; 
the reason for this discrepancy is not clear. Olsson et al. 
[19] found that after adjusting for starting age in the 
study, patients treated with GH had decreased risk for 
mortality in comparison with non-GH treated (HR 0.94; 
95% CI, 0.91–0.98, p = 0.0063); the latter group also 
included GH replete patients and other factors like radio-
therapy, body mass index, gender, different replacement 
therapies (on which further details were not provided) did 
not have a significant effect on the Cox model and were 
not selected for the final statistical model.
• Gonadotrophin deficiency: O’Reilly et al. [18] found that 
the mortality risk was higher in gonadotrophin deficient 
compared with gonadotrophin preserved patients after 
correction for factors reported above (Relative Risk 2.56; 
95% CI 1.10–5.96, p = 0.01); following sub-analysis of 
gonadotrophin deficiency according to sex, and after 
additional adjustment for dysfunction of all other pitui-
tary hormone axes, significant association with increased 
mortality remained only in men (Relative Risk 5.44; 95% 
CI, 1.07–27.69, p = 0.02). Interestingly, in this series, 
sex hormone replacement therapy was prescribed only 
for 79.8 and 21.5% of male and female gonadotrophin 
deficient patients, respectively. Ntali et al. [8] found that 
untreated gonadotrophin deficiency was not an independ-
ent predictor of survival, but in this study a very small 
percentage of deficient subjects had remained without 
sex hormone substitution.
• ACTH deficiency: Zueger et  al. [22], in a series of 
patients with NFA and ACTH deficiency concluded that 
the HR was 1 for patients on a total dose of hydrocor-
tisone between 5 and 19 mg daily but increased signifi-
cantly to 4 when the total dose was higher than 30 mg 
daily. In agreement with these findings, O’Reilly et al. 
[18] after multivariate analysis, found that the relative 
risk of death was increased in patients offered total daily 
dose of hydrocortisone higher than 30 mg (Relative 
Risk 3.79; 95% CI, 1.49–9.67, p < 0.01). These obser-
vations are also supported by Ntali et al. [8] who did 
not identify ACTH deficiency as a predictor of mortal-
ity; in this series, around 90% of the patients were on a 
lower dose, 20 mg total daily dose of hydrocortisone. 
Finally, Hammarstrand et al. [17] after Cox-regression 
analysis adjusted for age at the start of study, gender 
and radiotherapy, showed that patients receiving a daily 
hydrocortisone equivalent dose of more than 20 mg had 
significantly increased mortality compared to subjects 
not on glucocorticoid replacement (HR 1.88; 95% CI, 
1.06–3.33, p = 0.032).
• Thyroid-stimulating hormone (TSH) deficiency: In the 
study by O’Reilly et al. [18], the relative risk of death 
was increased in patients on levothyroxine daily dose 
less than 100 mcg. This finding needs to be interpreted 
cautiously as the levels of peripheral thyroid hormones 
achieved by each dose had not been taken into account. 
On the other hand, Ntali et al. [8] did not identify TSH 
deficiency as a predictor of mortality; in this series, levo-
thyroxine replacement was offered in a dose aiming to 
produce a free thyroxine level within the reference range 
(preferably in the upper half).
• Vasopressin deficiency: Treatment with desmopressin or 
diabetes insipidus have not been shown to be predictors 
of mortality in patients with NFA [8, 15, 18].
Other factors
Regrowth of the NFA, presentation with acute apoplexy, 
cavernous sinus invasion, extent of adenoma removal and 
repeat surgery for relapse were not predictors of mortality in 
a recent study [8]. Furthermore, larger tumor size (> 25 mm) 
and extent of NFA resection were not independent predictors 
of mortality either [13].
Conclusions and future perspectives
Based on the most recent literature, mortality in patients 
with NFA is increased with the survival being more com-
promised possibly in females and in patients diagnosed at an 
older age. The advances in the management of these patients 
(and particularly in the substitution of pituitary hormone 
deficits) has had a positive impact on survival. Nonethe-
less, further well designed and of adequate power studies 
are needed to establish the significance of other factors pre-
venting the achievement of mortality similar to that of the 
207Pituitary (2018) 21:203–207 
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general population. Series from non-European centers would 
also be valuable for this aim and would further expand the 
field.
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